Self-Emulsifying Cannabinoid Tablet Formulations by Fertin Pharma
Summary
Fertin Pharma A/S has filed USPTO Application US20260108543A1 for an orally dissolvable or chewable tableted powder formulation incorporating self-emulsifying systems loaded with at least 10% cannabinoids by weight. The formulation includes 20-80% water-soluble agents by weight, one or more flavors, and surfactants containing polyethylene glycol moieties. The application covers both liquid self-emulsifying systems (with surfactants, lipids, and isolated or synthetic cannabinoids) and solid self-emulsifying systems (with surfactants, waxes, and isolated or synthetic cannabinoids). Filing date was December 22, 2025.
About this source
USPTO classification A61K covers pharmaceutical preparations: formulations, dosage forms, combination therapies, delivery systems, and the vehicles that carry active ingredients. Every newly published application in A61K lands in this feed, around 245 a month. Applications publish 18 months after filing, so this feed reveals what pharma formulators at major sponsors and generics were working on in the prior year and a half. Watch this if you compete in drug formulation, file freedom-to-operate analyses, scout competitive drug products before clinical readouts, or follow novel delivery platforms like nanoparticles, lipid carriers, and long-acting injectables.
What changed
Fertin Pharma A/S has filed a new patent application with the USPTO for an orally dissolvable or chewable tableted powder formulation using self-emulsifying drug delivery systems for cannabinoids. The formulation comprises one or more carrier systems loaded with at least 10% cannabinoids by weight, combined with 20-80% water-soluble agents and flavoring agents. The application covers both liquid formulations (using surfactants, lipids, and cannabinoids) and solid formulations (using surfactants, waxes, and cannabinoids), with surfactants containing polyethylene glycol moieties.
Affected parties in the pharmaceutical and nutraceutical sectors developing cannabinoid-based oral delivery systems should review this patent filing to assess potential freedom-to-operate implications. Competitors working on self-emulsifying formulations for cannabinoids may need to design around this intellectual property once the patent grants.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Self-Emulsifying Systems For Cannabinoids
Application US20260108543A1 Kind: A1 Apr 23, 2026
Assignee
Fertin Pharma A/S
Inventors
Sanne Skov Jensen, Gitte Nykjær Nikolajsen, Simon Laursen, Dorthe Schackinger Boesen
Abstract
An orally dissolvable or chewable tableted powder formulation is presented. The formulation includes one or more carrier systems including one or more liquid or solid self-emulsifying systems loaded with cannabinoids in an amount of at least 10% by weight of the tableted powder formulation. The one or more self-emulsifying systems includes: at least one or more surfactants, one or more lipids and one or more isolated or synthetic cannabinoids when self-emulsifying system is a liquid self-emulsifying system, and at least one or more surfactants, one or more waxes and one or more isolated or synthetic cannabinoids when self-emulsifying system is a solid self-emulsifying system. The formulation further includes one or more water-soluble agents in an amount of 20-80% by weight of the tableted powder formulation and one or more flavors. The one or more surfactants includes one or more surfactants having a chemical structure that includes a polyethylene glycol moiety.
CPC Classifications
A61K 31/658 A61K 9/0056 A61K 9/4808 A61K 36/3482 A61K 47/02 A61K 47/10 A61K 47/14 A61K 47/26 A61K 47/44
Filing Date
2025-12-22
Application No.
19429281
Mentioned entities
Parties
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.